Accordingly, our findings suggest that imiquimod in combination with NF‐κB inhibitors or IAP antagonists [Geserick et al., Cell death and disease 2015; in press] may lead to further advances in melanoma treatment. The gene discussed is NFKB1; the disease is melanoma.